Search research articles
Contact Us
Filters
Showing results (121-130 of 232) with videos related to
Page
of 24
Sort By:
Gynecologic Oncology
|
November 4, 2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
Andrea E Wahner Hendrickson, Ann L Oberg, Gretchen Glaser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416
Afshin Dowlati, Kelly Robertson, Tomas Radivoyevitch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2010
Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome
Brigitte C Widemann, Frank M Balis, AeRang Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2011
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study
Steven G Dubois, Suzanne Shusterman, Ashish M Ingle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
Suresh S Ramalingam, Shivaani Kummar, John Sarantopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee
Lesley Seymour, S Percy Ivy, Daniel Sargent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors
Mrinal M Gounder, Lakshmi Nayak, Solmaz Sahebjam, et al.
Pediatric Blood & Cancer
|
October 2, 2012
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors
Margaret E Macy, Tracey Duncan, James Whitlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2019
Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN)
Holly A Massett, Grace Mishkin, Jeffrey A Moscow, et al.
Lancet (London, England)
|
August 14, 2022
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials
Dai Chihara, Ruitao Lin, Christopher R Flowers, et al.
Page
of 24
Search research articles
Search
Showing results (121-130 of 232) with videos related to
Sort By:
Page
of 24
Gynecologic Oncology
|
November 4, 2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
Andrea E Wahner Hendrickson, Ann L Oberg, Gretchen Glaser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416
Afshin Dowlati, Kelly Robertson, Tomas Radivoyevitch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2010
Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome
Brigitte C Widemann, Frank M Balis, AeRang Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2011
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study
Steven G Dubois, Suzanne Shusterman, Ashish M Ingle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
Suresh S Ramalingam, Shivaani Kummar, John Sarantopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee
Lesley Seymour, S Percy Ivy, Daniel Sargent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors
Mrinal M Gounder, Lakshmi Nayak, Solmaz Sahebjam, et al.
Pediatric Blood & Cancer
|
October 2, 2012
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors
Margaret E Macy, Tracey Duncan, James Whitlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2019
Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN)
Holly A Massett, Grace Mishkin, Jeffrey A Moscow, et al.
Lancet (London, England)
|
August 14, 2022
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials
Dai Chihara, Ruitao Lin, Christopher R Flowers, et al.
Page
of 24